QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.107.016485v1 35/9/1649    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Husain, A. Articles by Hein, D. W. Search for Related Content PubMed PubMed Citation Articles by Husain, A. Articles by Hein, D. W.

Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence Elements

Department of Pharmacology & Toxicology, James Graham Brown Cancer Center and Center for Environmental Genomics & Integrative Biology, University of Louisville School of Medicine, Louisville, Kentucky

(Received May 2, 2007; accepted June 21, 2007)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Arylamine N-acetyltransferase 1 (NAT1) plays an important role in the biotransformation of xenobiotics, and genetic variants have been implicated in susceptibility to cancer and birth defects. A specific and quantitative reverse transcription-polymerase chain reaction assay for transcription from the major NAT1 promoter detected high expression with limited variability in human tissues. A 213-base pair (bp) minimal promoter was identified by transfection of luciferase reporter constructs into MCF-7 and HepG2 cell lines. Alignment of the 213-bp region with paralogous and orthologous promoters revealed two conserved region segments, one of which overlaps a 16-bp perfect palindrome. Transfection of luciferase constructs with artificial mutations in the minimal promoter defined two sites important for promoter function. One of these sites included a close match to the Sp1 transcription factor binding consensus sequence. Electrophoretic mobility shift assays (EMSAs), followed by competitive and supershift analyses, confirmed the Sp1 binding. Mutation of the highly conserved portion of the 16-bp palindrome reduced promoter activity more than 3-fold, and an EMSA shift was detected with an oligonucleotide, 200L29, which spans this segment. The 200L29 EMSA shift could not be competed by consensus Sp1 or AP-2 oligonucleotides, and may represent binding of a transcription factor that is common to N-acetyltransferase genes in humans and other species.

Numerous studies have documented interindividual differences in NAT1 protein or enzyme activity in diverse human tissues including erythrocytes (Bruhn et al., 1999), intestine (Hickman et al., 1998), colon (Ilett et al., 1994), skin (Kawakubo et al., 2000), breast (Williams et al., 2001), placenta (Upton et al., 2000), and prostate (Al-Buheissi et al., 2006) with no known genetic basis. Although the NAT1 alleles NAT1^*14B, ^*15, ^*17,^*19, and ^*22 are known to encode proteins with low enzyme activity (Fretland et al., 2001), these forms are rare in humans and variable activity has also been reported for individuals homozygous or heterozygous for the most frequent NAT1^*4 and ^*10 alleles. Some of the observed variability is likely due to post-translational effects caused by intracellular redox or metabolic status (Butcher et al., 2000, 2004; Rodrigues-Lima and Dupret, 2004), but the influence of NAT1 transcriptional regulation has not yet been determined.

Two alternative NAT1 promoters, recently renamed NATa and NATb (Minchin et al., 2007), are respectively located 51.5 kb and 11.8 kb upstream of the single translated exon. Transcription of NAT1 occurs in a wide variety of tissues and cell lines and most mRNAs are initiated at NATb (Husain et al., 2004; Boukouvala and Fakis, 2005; Butcher et al., 2005). The alternative promoter, NATa, is most highly expressed in a few tissues, including kidney, liver, lung, and trachea (Barker et al., 2006). The pattern of placental NAT1 expression during human development (Smelt et al., 2000) and the temporal and spatial expression of mouse Nat2, the likely ortholog of human NAT1, during cardiogenesis and at neural closure (Wakefield et al., 2005), are probable examples of transcriptional regulation. An androgen analog was recently shown to increase NAT1 mRNA by stimulation of transcription initiation at NATb in two prostate cancer cell lines (Butcher et al., 2007). The high expression of NAT1 in many estrogen receptor-positive breast tumors is also apparently due to higher mRNA production (Perou et al., 2000; Adam et al., 2003; Sorlie et al., 2003; Tozlu et al., 2006). Further understanding of the increased NAT1 expression in breast tumors is of interest because of the role of NAT1 in biotransforming environmental carcinogens and the observed association of higher NAT1 expression with better patient survival (Bieche et al., 2004; Dolled-Filhart et al., 2006). Further characterization of the NATb promoter is presented here, including quantitation of expression in diverse human tissues and identification of specific functional elements within the minimal promoter sequence.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Human RNA Samples. Two panels of pooled, purified, tissue-specific, human total RNAs from Ambion Inc. (Austin, TX) and BD Biosciences Clontech (Palo Alto, CA) and RNAs from the HepG2, HT-29, MCF-7, SW480, Caco-2, HEK293, and A549 human cell lines were as described previously (Barker et al., 2006; Husain et al., 2007). A sample of breast RNA from one female and a liver RNA sample from one male were also obtained from Ambion. Additional RNAs representing adrenal gland, bladder, and liver were obtained from BD Biosciences Clontech.

Quantitative Real-Time RT-PCR. TaqMan analysis was performed using the ABI 7700 sequence detection system (Applied Biosystems, Foster City, CA). The 20-µl PCR reactions were 1x TaqMan Universal Master Mix, with 300 nM forward and reverse primers and 100 nM probe. The sequence of the NATb-specific forward primer (Table 1) is within the first exon of the major NAT1 mRNA. The sequences of the reverse primer and the probe (Table 1) are within the NAT1 open reading frame exon and the 79-base 5'-untranslated exon, respectively. For PCR, initial incubations at 50°C for 2 min and 94°C for 10 min were followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Quantitation of the endogenous control 18S ribosomal RNA was performed using TaqMan Ribosomal RNA Control Reagents for 18S ribosomal RNA (Applied Biosystems). Four microliters of diluted cDNA, equivalent to 40 ng of the initial RNA template, was used in each PCR. Two independent RT reactions were prepared for each RNA and TaqMan measurements were carried out in duplicate for each cDNA product, for a total of four readings. Controls and calculations of relative mRNA quantity were as described previously (Barker et al., 2006). For each RT set, the relative measures obtained from the two real-time runs were averaged and normalized with respect to the average of all samples in the same RT group.

Construction of pGL3-Basic Promoter Clones and Artificial Mutant Derivatives. For construction of NATb promoter segment clones, DNA from the BAC CTD2547-L16 was used as template for PCR with the high fidelity Phusion polymerase (New England Biolabs, Ipswich, MA) using primers with artificial 5' HindIII sites (Table 1), followed by cloning into the HindIII site of pGL3-Basic (Promega, Madison, WI). Artificial mutant derivatives of the 318-bp promoter fragment were constructed as described previously (Ho et al., 1989) or with the modification that restriction enzyme digestion and ligation with T4 DNA ligase was used to accomplish fusion of the primary PCR products. Template DNAs for site-directed mutagenesis were either the genomic BAC clone CTD2547L16, the 318 promoter plasmid, or, for the construction of the double mutant, a derivative of the 318 promoter plasmid carrying a Dup1-R7 mutation. Primers with mutant sequences and outer nested primers appropriate to each template were used (Table 1). The final inner nested PCR was carried out with primers NATb 318H3, and NAT1TSSZeroRevH3 (Table 1), and the resulting products were cloned into the HindIII site of pGL3-Basic. The presence of mutations was monitored by restriction enzyme digestion and verified by sequencing of plasmid DNAs with the ABI Big Dye Termination Reagents and the 310 Genetic Analyzer (Applied Biosystems).

View larger version (33K): [in this window] [in a new window]   FIG. 1. Relative expression of NATb mRNA in 29 different human tissues. Series A includes human tissue RNAs primarily from the Ambion test panel and series B includes human tissue RNAs primarily from the BD test panel. An additional liver sample from BD, labeled Liver (BD Ref), was included as a point of reference in the measurements of both series. Fifteen of the 29 tissues are represented, from independent sources, in both series A and B. Error bars indicate the full range of measured values (n = 2).

Transcription Factor Database Analysis. TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html), MatInspector Release 7.4 (http://www.genomatix.de/products/MatInspector/index.html), Alibaba 2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/index.html), and CONREAL (http://conreal.niob.knaw.nl/) were used to identify candidate transcription factor binding sites. Putative binding sites were considered plausible based on finding at least a 75% match with the consensus sequence and on matrix similarity thresholds as defined at each database. TRANSFAC (http://www.gene-regulation.com/pub/databases.html) was the source of the Sp1 consensus matrix M00196.

Electrophoretic Mobility Shift Assay. Nuclear extracts were prepared from MCF-7 cells using the Transfactor Extraction Kit (BD Biosciences Clontech) as described by the manufacturer. The crude nuclear pellet was resuspended in 20 mM HEPES pH 7.9, 1.5 mM MgCl₂, 0.42 M NaCl, 0.2 mM EDTA, 25% glycerol, 1 mM dithiothreitol containing 1x Complete Protease Inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and disrupted by repeated passaging through a 27-gauge needle. The soluble supernatant was collected after centrifugation at 14,000g for 10 min at 4°C. The protein concentration, typically about 2 µg/µl, was measured with the Bradford Reagent kit (Bio-Rad, Hercules, CA). Single-stranded oligonucleotides were 5'-labeled with -[³²P]ATP (3000 Ci/mmol, 150 mCi/ml) (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and T4 polynucleotide kinase (New England Biolabs) and purified with Sephadex G-25 spin columns (GE Healthcare). Radiolabeled oligonucleotides were annealed with a 2-fold molar excess of the unlabeled complementary oligonucleotide by incubation at 65°C for 5 min and 37°C for 15 min in 20 mM Tris-HCl (pH 8), 1 mM EDTA, and 50 mM NaCl. Binding reactions for EMSA contained 5 µg of nuclear extract in 10 mM Tris-HCl (pH 7.6), 50 mM NaCl, 1 mM MgCl₂, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol, and 400 ng of poly(dI-dC):poly(dI-dC) (GE Healthcare) nonspecific competitor in 20 µl. Reactions were incubated at room temperature for 10 min before addition of 40 fmol of probe and continued incubation for 20 min. Competition reactions included a 125-fold molar excess of unlabeled competitor added to the initial incubation. For supershift assays, 1 to 2 µl of TransCruz gel shift antibody (200 µg/ml) against Sp1 (PEP2, catalog number sc-59x; Santa Cruz Biotechnology, Santa Cruz, CA) was added to the reaction mixture and incubated for 20 to 30 min at room temperature subsequent to incubation of oligonucleotide probes with nuclear extract. DNA-protein complexes were resolved by electrophoresis through 20 x 15 cm, 4% nondenaturing (29:1) polyacrylamide gels containing 2% glycerol, 22.5 mM Tris base, 22.5 mM boric acid, and 0.5 mM EDTA. Gels were prerun at 250 V, loaded, and run at 350 V for 55 to 65 min, with cooling to 20°C by a circulating water bath (Protean2 Xi Cell; Bio-Rad). Gels were exposed for 25 to 30 min to a PhosphorImager screen for analysis by a Storm 860 Imager scanner (GE Healthcare).

	Results

Top Abstract Materials and Methods Results Discussion References

 
Quantitative RT-PCR analysis of two panels of diverse human tissue RNAs was performed using an intron-spanning primer pair, with the forward primer specific for mRNA originating at the NATb promoter. Results of testing 44 samples from 29 different tissues, including 15 tissues represented in both panels, are shown in Fig. 1. Some variability in NATb mRNA was evident among the different tissues and occasionally between different samples of the same tissue type, but most samples fell within an approximately 10-fold range. The duplicate samples of colon, kidney, lung, prostate, small intestine, and testis all fell in the higher end of this range, whereas the duplicate samples of brain and skeletal muscle had consistently lower levels of NATb mRNA. However, the relative quantitative differences between tissues were not always consistent. In series A, for instance, the small intestine sample had more than 3-fold higher mRNA than the prostate sample, but in series B, the prostate level was 4-fold that of small intestine. Also in series A, mRNA in trachea was 5.5-fold higher than that of bladder, but in series B, the bladder level was 2.8-fold higher than that of trachea. Results of quantitative RT-PCR analysis of RNAs prepared from selected human cell lines are shown in Fig. 2. The range of NATb expression in most of the cell lines was similar to that found in the human tissue samples (Fig. 1). The expression of NATb was highest in the MCF-7 breast tumor line and notably higher than any normal tissue, at more than 120-fold the expression of the reference liver sample.

View larger version (12K): [in this window] [in a new window]   FIG. 2. Relative expression of NATb mRNA in human cell lines. The sample labeled Liver (BD Ref) was included to provide a point of reference with the human tissue measurements. Error bars indicate the full range of measured values (n = 2).

View larger version (15K): [in this window] [in a new window]   FIG. 3. Definition of the NATb minimal promoter by transient transfection of MCF-7 and HepG2 cell lines. Promoter strengths were assessed by dual luciferase assay and measurements ± S.E.M. are presented. Lines at the left indicate the approximate boundaries of the segments tested with respect to the diagrammed genomic DNA, including the minimal promoter, indicated by the open box, and the region containing transcription start sites, indicated by the bracket labeled TSS.

The minimal NATb promoter region was assessed for potentially functional sequence elements by comparison with paralogous and orthologous promoter sequences. The alignment of NATb with promoter sequences from human NAT2 and orthologous genes from rat, mouse, and cow is shown in Fig. 4. A high degree of similarity was evident for all of these sequences, but with two particularly strong regions of conservation. At positions 37 to 55 in the NATb segment shown in Fig. 4, 15 of 19 of the nucleotides in the sequence CTGCAACTACATTTCCCAG were found in all six promoters. A second conserved region, CTTCCCCTGCAG, occurred at positions 120 to 131 in the NATb sequence, with 8 of 12 of these nucleotides identical in all of the compared promoters. The alignment also showed that of two functional sites previously identified in the mouse Nat2 promoter (Boukouvala et al., 2003), the Sp1 site at positions 81 to 90 in the mouse Nat2 promoter was identical to the NATb sequence at 9/10 positions, but the mouse Nat2 TATA box sequence was not apparent in NATb or any of the other promoters shown in Fig. 4.

View larger version (83K): [in this window] [in a new window]   FIG. 4. Alignment of promoter regions of N-acetytransferase genes from human NAT1 NATb (Hs NAT1), human NAT2 (Hs NAT2), mouse Nat1 (Mm Nat1), mouse Nat2 (Mm Nat2), rat (Rn Nat), and cow (Bt Nat). Nucleotides conserved in all six sequences are indicated by an asterisk. On the consensus sequence line, nucleotides present in all six promoters are shown in bold and nucleotides present in five of the six sequences are shown in plain font. A putative TATA box and an Sp1 site in the mouse Nat2 promoter are italicized. Two regions of high sequence conservation are indicated by thick underlining in the NATb promoter sequence. The bold italicized sequence near the 3'end of Rn Nat is the splice donor site defined by cDNAs U01343, U01347, and U01348. The bold italicized sequences near the 3' ends of the Hs NAT1 and Hs NAT2 sequences are the splice sites detected in 5'-RACE clones and database cDNAs (Husain et al., 2004, 2007). The bold italicized sequence near the 3' end of the Mm Nat2 sequence is the donor splice site defined by all three of the mouse Nat2 cDNAs CA494799, CN663986, and BF164333. The bold italicized sequence near the 3' end of Bt Nat is the splice donor site defined by the splicing pattern of the BT025447, CK946692, BE683786, CK960222, DY464402, AW484954, and BG689007 cDNAs. Genomic sequences were retrieved at the Genome Browser Gateway and aligned using ClustalW as detailed under Materials and Methods.

View larger version (27K): [in this window] [in a new window]   FIG. 5. Summary of candidate functional elements in the NATb promoter and the nine different sequence alterations present in artificially mutated constructs. The sequences of EMSA oligonucleotides 200L29 and 165L26 are also shown. Nucleotides in bold on the genomic sequence line are conserved in all six of the promoters shown in Fig. 4. The labels c213, c178, and c150 mark the positions of the 5' ends of the genomic segments present in the NATb 213-, 178-, and 150-bp promoter luciferase constructs, respectively. The nucleotides labeled 5'-TSS and 3'-TSS delimit the region including previously identified NATb transcription start sites (Husain et al., 2004).

View larger version (21K): [in this window] [in a new window]   FIG. 6. Results of promoter strength assays ± S.E.M., with deleted and artificially mutated NATb promoter constructs. Duplicate test constructs were assessed by transfections of MCF-7 and HepG2 cell lines and dual luciferase assay (N 3). Details of the artificial mutations are shown in Fig. 5.

A partial deletion combined with two nucleotide changes in the putative Sp1 site, Sp1 del4+GCAT (cggggc>at), reduced promoter activity nearly 10-fold in both MCF-7 and HepG2. A second mutation, Sp1 G3G4AT, changing only the two most conserved positions of the consensus Sp1 sequence, as defined by TRANSFAC M00196, also resulted in a large reduction of promoter activity. The NFY-6 mutation in the putative NF-Y site reduced promoter activity slightly, with a 50% reduction in MCF-7 and a 33% reduction in HepG2. Alteration of a putative AP-1 transcription factor binding site (Fig. 5) caused no change in measured promoter activity. No notable effect on promoter activity was observed in the construct with two mutant regions that altered the 5' portion of the 12-nucleotide conserved region and changed both elements of the 13-nucleotide duplicated segment, Dup1-R7+Dup2-L6 (Fig. 5).

The two different segments of the NATb promoter in which mutations showed large effects on relative promoter activity were tested by EMSA to investigate the nature and specificity of protein binding. The oligonucleotide 165L26 containing the putative NATb Sp1 site was shifted by MCF-7 nuclear extract with a shift pattern closely related to the shift pattern seen with a consensus Sp1 recognition site oligonucleotide (Fig. 7A). The 165L26 shift also was effectively competed by addition of an excess of the consensus Sp1 oligonucleotide (Fig. 7A). Figure 7B shows that an anti-Sp1 antibody caused a supershift of the 165L26 complex identical to the supershift seen for the Sp1 consensus oligonucleotide complex. Incubation with nuclear extract from MCF-7 cells also specifically shifted the oligonucleotide 200L29, which spans the sequences altered by the Con1-L9 and Pal 11/16 mutations. Competition with unlabeled oligonucleotides including consensus recognition sequences for AP-2 or Sp1 did not abolish this binding, nor did competition by the 165L26 oligonucleotide that corresponds to the NATb Sp1 site (Fig. 7C).

View larger version (91K): [in this window] [in a new window]   FIG. 7. Summary of EMSA analysis of oligonucleotides 165L26 and 200L29. A, comparison of binding of MCF-7 nuclear extract to Sp1 consensus and 165L26 oligonucleotides and competition with 165L26 binding. Lane 1: Sp1 probe+extract; lane 2: Sp1 probe only; lane 3: 165L26 probe+extract; lane 4: 165L26 probe+extract+Sp1 competitor; lane 5: 165L26 probe+extract+Ap-2 competitor; lane 6: 165L26 probe+extract+Ap-1 competitor; lane 7: 165L26 probe only. B, supershift of Sp1 consensus and 165L26 complexes with Sp1 antibody. lane 1: Sp1 consensus probe+extract; lane 2: Sp1 consensus probe+extract +anti-Sp1 Ab; lane 3: Sp1 consensus probe+extract+anti-Ap-2 antibody; lane 4: Sp1 consensus probe only; lane 5: 165L26 probe+extract; lane 6: 165L26 probe+extract+anti-Sp1 Ab; lane 7: 165L26 probe+extract+anti-Ap-2 Ab; lane 8: 165L26 probe only. C, binding and competition of 200L29 oligonucleotide. lane 1: 200L29 probe+extract; lane 2: 200L29 probe+extract+Ap-2 consensus competitor; lane 3: 200L29 probe+extract+unlabeled 200L29 competitor; lane 4, 200L29 probe+extract+Sp1 consensus competitor; lane 5: 200L29 probe+extract+165L26 competitor; lane 6: 200L29 probe only.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
A quantitative RT-PCR assay that uses intron-spanning primers and is specific for transcripts from the NAT1 major promoter showed that 44 samples from pooled mRNA preparations representing 29 different human tissues exhibited high expression of the NATb promoter with moderate variation between tissues. These results support the general view that NAT1b mRNA is highly expressed in essentially all tissues, but more extensive analyses with larger numbers of samples from each tissue will be needed to determine the full range of variable expression for each tissue and whether there are consistent trends for intertissue differences. Although conclusions would be strengthened by examining additional samples and more types of human tissues, these observations are generally consistent with previously published NAT1 quantitative RT-PCR data for human tissues, obtained with primers from the 3' terminus of the gene, which did not distinguish transcripts from the alternative NAT1 promoters (Adam et al., 2003). The ubiquitous expression of NATb is in contrast to NAT2, since high-level expression of the NAT2 promoter is limited to liver, colon, and small intestine with up to 1000-fold differences in expression between the highest and lowest expressing tissues (Husain et al., 2007). The alternative NAT1 promoter, NATa, is most highly expressed in a small number of tissues, including kidney, liver, lung, and trachea (Barker et al., 2006). Thus, the measurements reported here support the view that expression of NAT1 in diverse tissues is primarily due to transcription of NATb. Future investigations monitoring the relative functionality of the alternative promoters will be facilitated by use of the NATb-specific TaqMan assay used here, together with the previously described NATa-specific TaqMan assay (Barker et al., 2006), which differs only in the sequence of the forward primer.

Transfection of luciferase expression constructs with progressive deletions defined a minimal NATb promoter with high transcription strength, comparable to the CMV promoter in the pGL3-Control plasmid, in both the MCF-7 and HepG2 cell lines. The 213-bp minimal promoter construct eliminates an additional 173 bp from the 5' end of the pGL-257 minimal promoter described previously (Butcher et al., 2005). Two important functional sites were localized in this minimal region by further deletion and mutation analyses. The presence of a functional Sp1 site was strongly implicated by a conserved alignment with an Sp1 site described previously for the mouse Nat2 promoter (Boukouvala et al., 2003) and maximal similarity to the TRANSFAC Sp1 consensus matrix M00196. Mutations in the putative Sp1 site caused sharp reductions in the promoter activity of luciferase reporter constructs. The results of EMSA binding, competition, and supershift assays provided direct evidence for binding of Sp1 to this segment of the NATb promoter. Sp1 binding is also likely to be an important feature of the promoter activity of the rat, mouse, and bovine promoters, since most of these have a highly similar sequence that aligns with the NATb Sp1 site (Fig. 4) and matches well with the M00196 Sp1 consensus matrix. Mouse Nat1 and Nat2 are both expressed in a wide range of tissues (Sugamori et al., 2003; Loehle et al., 2006), but little is known concerning tissue-specific expression of the bovine or rat genes. The human NAT2 promoter is notably divergent at the Sp1 site location, however, and shows multiple sequence discordances with highly conserved positions in the M00196 matrix. Since Sp1 is ubiquitously expressed and usually stimulates transcription (Philipsen and Suske, 1999), the absence of a functional Sp1 site in the NAT2 promoter is likely relevant to the limited tissue specificity of high level expression of NAT2 in humans.

A second critical region of the NATb promoter was initially identified by the presence of a highly conserved sequence and an overlapping 16-nucleotide palindrome. It has previously been suggested that transcription factors AP-2 and/or OLF-1 may bind at this site based on a MatInspector analysis (Butcher et al., 2005). Two non-overlapping mutations in this region, Con1-R7 and Pal 11/16, both caused substantial reductions in promoter activity, but absence of the entire segment in the NATb 178 deletion construct did not cause any greater reduction, suggesting that a single functional component of the transcription complex may be affected, although the region may contain binding sites for multiple proteins. EMSA analysis with the 200L29 oligonucleotide spanning this segment demonstrated a specific shift that was not competed by consensus Sp1 or AP-2 oligonucleotides. The exact 16-bp palindrome in NATb was not found in the other promoters shown in Fig. 4, but 9 of 16 of the nucleotides in this segment did show complete conservation, consistent with the presence of a functional element. Further evidence of an important functional site at this location was provided by review of the conservation analysis of the chr8:18,110,586 to 18,113,015 (March 2006 Assembly) segment in the Human Genome Browser Database. The presence of similar sequences in human, mouse, rat, elephant, cow, armadillo, chimpanzee, rhesus monkey, and rabbit is indicated by an isolated, sharp peak of conservation that corresponds to nucleotides 42 to 57 of the NATb promoter. Transcription factor binding at this site is likely to be important for the expression of N-acetyltransferase genes across several species.

Although mutations in several of the candidate sites with conserved or distinctive sequence structures (Fig. 5) had little or no effect on promoter activity in this assay system, it remains possible that they may have functional significance during embryonic development, in the mediation of specific physiological responses in vivo, or in the context of normal chromatin and chromosomal structures. It is also possible that sequences outside the 213-bp segment have important functions that are not detectable under our specific experimental conditions, as exemplified by the recent identification of a region that lies 5' to the 213-bp minimal promoter and mediates a transcriptional response to androgens in two prostate cancer cell lines (Butcher et al., 2007).

Knowledge of the location of critical sequences within the NATb promoter is also important for assessing the possible functional significance of single-nucleotide polymorphisms (SNPs) located in the promoter region. Based on information available at the Human Genome Browser Gateway (http://www.ncbi.nlm.nih.gov/SNP/index.html) and the National Institute of Environmental Health Sciences Environmental Genome Project (http://egp.gs.washington.edu/), two SNPs, rs28359482 and rs28359483, can be identified within the sequence of the minimal 213 promoter segment, at positions 85 and 228 of the sequence shown in Fig. 5. The rs28359482 SNP is adjacent to the NATb Sp1 site, but the TC change does not affect the match to the Sp1 consensus matrix M00196. The rs28394583 GA SNP is an intronic SNP that lies just 3' to the consensus splice donor site of the NATb start exon. The locations of these SNPs indicate little likelihood of large functional effects. Further characterization of NAT1 transcription is required to address the possibility of functional polymorphisms in control regions that are not part of the NATb minimal promoter or in intronic sequences that affect transcription or splicing of the NAT1 mRNA.

	Footnotes

 
This work was partially supported by National Institutes of Health Grants CA34627 and ES12557. Portions of this work constituted partial fulfillment for the Ph.D. in Pharmacology and Toxicology awarded to A.H. from the University of Louisville.

doi:10.1124/dmd.107.016485.

ABBREVIATIONS: NAT, N-acetyltransferase; 5'-RACE, 5' rapid amplification of cDNA ends; BAC, bacterial artificial chromosome; bp, base pair; EMSA, electrophoretic mobility shift assay; kb, kilobase pair; RT, reverse transcription; PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism; TF, transcription factor; TSS, transcription start site.

Address correspondence to: David W. Hein, Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292. E-mail: d.hein{at}louisville.edu

	References

Top Abstract Materials and Methods Results Discussion References

 


Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, et al. (2003) Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1: 826-835.[Abstract/Free Full Text]

Al-Buheissi SZ, Cole KJ, Hewer A, Kumar V, Bryan RL, Hudson DL, Patel HR, Nathan S, Miller RA, and Phillips DH (2006) The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures. Prostate 66: 876-885.[CrossRef][Medline]

Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, and Hein DW (2006) Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 16: 515-525.[Medline]

Bieche I, Girault I, Urbain E, Tozlu S, and Lidereau R (2004) Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 6: R252-R263.[CrossRef][Medline]

Boukouvala S and Fakis G (2005) Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 37: 511-564.[CrossRef][Medline]

Boukouvala S, Price N, Plant KE, and Sim E (2003) Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice. Biochem J 375: 593-602.[CrossRef][Medline]

Bruhn C, Brockmoller J, Cascorbi I, Roots I, and Borchert HH (1999) Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 58: 1759-1764.[CrossRef][Medline]

Butcher NJ, Arulpragasam A, Goh HL, Davey T, and Minchin RF (2005) Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochem J 387: 119-127.[CrossRef][Medline]

Butcher NJ, Arulpragasam A, and Minchin RF (2004) Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem 279: 22131-22137.[Abstract/Free Full Text]

Butcher NJ, Ilett KF, and Minchin RF (2000) Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol 57: 468-473.[Abstract/Free Full Text]

Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, and Minchin RF (2007) Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 67: 85-92.[Abstract/Free Full Text]

Carmichael SL, Shaw GM, Yang W, Iovannisci DM, and Lammer E (2006) Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. Am J Med Genet A 140: 1915-1922.[Medline]

Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, and Rimm DL (2006) Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12: 6459-6468.[Abstract/Free Full Text]

Ebisawa T and Deguchi T (1991) Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 177: 1252-1257.[CrossRef][Medline]

Ebisawa T, Sasaki Y, and Deguchi T (1995) Complementary DNAs for two arylamine N-acetyltransferases with identical 5' non-coding regions from rat pineal gland. Eur J Biochem 228: 129-137.[Medline]

Fretland AJ, Doll MA, Leff MA, and Hein DW (2001) Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 11: 511-520.[CrossRef][Medline]

Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42.[Abstract/Free Full Text]

Hein DW, Trinidad A, Yerokun T, Ferguson RJ, Kirlin WG, and Weber WW (1988) Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. Drug Metab Dispos 16: 341-347.[Abstract]

Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, and Sim E (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42: 402-409.[Abstract/Free Full Text]

Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.[CrossRef][Medline]

Husain A, Barker DF, States JC, Doll MA, and Hein DW (2004) Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 14: 397-406.[CrossRef][Medline]

Husain A, Zhang X, Doll MA, States JC, Barker DF, and Hein DW (2007) Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35: 721-727.[Abstract/Free Full Text]

Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, and Minchin RF (1994) Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 47: 914-917.[CrossRef][Medline]

Jensen LE, Hoess K, Mitchell LE, and Whitehead AS (2006) Loss of function polymorphisms in NAT1 protect against spina bifida. Hum Genet 120: 52-57.[CrossRef][Medline]

Kawakubo Y, Merk HF, Masaoudi TA, Sieben S, and Blomeke B (2000) N-Acetylation of paraphenylenediamine in human skin and keratinocytes. J Pharmacol Exp Ther 292: 150-155.[Abstract/Free Full Text]

Kent WJ (2002) BLAT—the BLAST-like alignment tool. Genome Res 12: 656-664.[Abstract/Free Full Text]

Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, and Haussler D (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.[Abstract/Free Full Text]

Loehle JA, Cornish V, Wakefield L, Doll MA, Neale JR, Zang Y, Sim E, and Hein DW (2006) N-Acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther 319: 724-728.[Abstract/Free Full Text]

McQueen CA and Chau B (2003) Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity. Toxicol Sci 73: 279-286.[Abstract/Free Full Text]

Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F and Butcher NJ (2007) Arylamine N-acetyltransferase I. Int J Biochem Cell Biol.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.[CrossRef][Medline]

Philipsen S and Suske G (1999) A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 27: 2991-3000.[Abstract/Free Full Text]

Rodrigues-Lima F and Dupret JM (2004) Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and nongenetic factors. Curr Pharm Des 10: 2519-2524.[CrossRef][Medline]

Smelt VA, Upton A, Adjaye J, Payton MA, Boukouvala S, Johnson N, Mardon HJ, and Sim E (2000) Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet 9: 1101-1107.[Abstract/Free Full Text]

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad SciUSA 100: 8418-8423.[Abstract/Free Full Text]

Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 64: 170-179.[Abstract/Free Full Text]

Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, and Bieche I (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13: 1109-1120.[Abstract/Free Full Text]

Upton A, Smelt V, Mushtaq A, Aplin R, Johnson N, Mardon H, and Sim E (2000) Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim Biophys Acta 1524: 143-148.[Medline]

Wakefield L, Cornish V, Broackes-Carter F, and Sim E (2005) Arylamine N-acetyltransferase 2 expression in the developing heart. J Histochem Cytochem 53: 583-592.[Abstract/Free Full Text]

Williams JA, Stone EM, Fakis G, Johnson N, Cordell JA, Meinl W, Glatt H, Sim E, and Phillips DH (2001) N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics 11: 373-388.[CrossRef][Medline]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.107.016485v1 35/9/1649    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Husain, A. Articles by Hein, D. W. Search for Related Content PubMed PubMed Citation Articles by Husain, A. Articles by Hein, D. W.